The placebo controlled, randomized and single blind trial is intended to investigate the safety and efficacy o f ADXS-HPV in around three different dose cohorts.
The company expects to release the low dose results in early 2012.
Advaxis chairman /CEO Thomas Moore said the six-month follow-up evaluation for this cohort will be completed by this January.
"The mid-dose leg will begin recruitment immediately," Moore said.